Prosecution Insights
Last updated: April 19, 2026
Application No. 18/252,217

3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS

Final Rejection §102§103§112
Filed
May 09, 2023
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Merck Sharp & Dohme LLC
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
2y 7m
To Grant
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
1201 granted / 1604 resolved
+14.9% vs TC avg
Strong +15% interview lift
Without
With
+15.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
46 currently pending
Career history
1650
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
5.8%
-34.2% vs TC avg
§102
16.9%
-23.1% vs TC avg
§112
52.3%
+12.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1604 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-12 and 15-18 are pending in the application. This action is in response to applicants' amendment dated February 2, 2026. Claims 1-3, 5, 8 and 11 have been amended, claim 13 has been canceled and claims 17 and 18 are newly added. Response to Amendment Applicant's arguments filed February 2, 2026 have been fully considered with the following effect: The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1a), b), c), d), e), f) and h) in the last office action, which are hereby withdrawn. However, with regards to the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1g) of the last office action, the applicant’s amendments and remarks have been fully considered but they are not persuasive. g) The applicants’ stated that the rejection has been obviated by the claim amendment that corrects the obvious typographical error by superscripting the “4” in the species as “14-methoxy-“ in claim 11. However, the applicants failed to correct both species, i.e. the species in lines 7-9 and 16-18 on page 18 of the previous amendment which corresponds to the species in lines 8-10 and 15-17 on page 15 of the amendment filed February 2, 2026. The species in lines 8-10 has been amended but the species in lines 15-17 has not. Claim 11 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(d) or 35 U.S.C. 112 (pre-AIA ), 4th paragraph rejection, labeled paragraph 2) in the last office action, which is hereby withdrawn. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 102(a)(2), anticipation rejection/ 35 U.S.C. 103, obviousness rejection, labeled paragraph 3) in the last office action, which is hereby withdrawn. With regards to the 35 U.S.C. 102(a)(2), anticipation rejection/ 35 U.S.C. 103 obviousness rejection, labeled paragraph 4) in the last office action, the applicants failed to comment on this ground of rejection and is therefore herein maintained. Claim(s) 1-13 and 15-18 is/are rejected under 35 U.S.C. 102(a)(2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Pennington et al., U.S. Patent Application Publication No. 2024/0368182 and U.S. Patent No. 12,006,330, for reasons of record. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 09, 2023
Application Filed
Sep 08, 2025
Non-Final Rejection — §102, §103, §112
Feb 02, 2026
Response Filed
Mar 19, 2026
Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595228
PROCESS FOR SYNTHESIZING TRIARYLMETHANE SULFONE COMPOUNDS
2y 5m to grant Granted Apr 07, 2026
Patent 12595259
AMINOPYRIDINE COMPOUND
2y 5m to grant Granted Apr 07, 2026
Patent 12590081
FUSED IMIDAZOLE DERIVATIVES, PREPARATION METHOD AND MEDICINAL USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12575569
METHODS OF CONTROLLING OR PREVENTING INFESTATION OF RICE PLANTS BY THE PHYTOPATHOGENIC MICROORGANISM GIBBERELLA FUJIKUROI
2y 5m to grant Granted Mar 17, 2026
Patent 12577262
FUNCTIONALIZED GOLD CARBENE NAPTHAQUINONE COMPLEXES FOR USE IN THE TREATMENT OF CANCER
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.4%)
2y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 1604 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month